Inspira Technologies Deploys Advanced Life-Support Systems in Leading U.S. Hospital

Inspira Technologies (NASDAQ: IINN) has announced the delivery of its INSPIRA ART100 cardiopulmonary bypass systems to Glo-Med Networks Inc., marking a significant step in revolutionizing critical care. The systems are being prepared for deployment at a leading New York hospital, ranked among the top 15% of cardiothoracic programs in the U.S.

Designed in collaboration with top U.S. clinicians, the INSPIRA ART100 enhances extracorporeal blood circulation with cutting-edge technology and intuitive design, offering optimized patient care during complex procedures. The deployment will be supported by Inspira and Glo-Med teams to ensure seamless integration into clinical workflows.

The rollout also highlights Inspira’s strategic focus on partnerships with premier medical institutions, aiming to introduce its advanced technologies to physicians and perfusionists.

In addition to the INSPIRA ART100, the company is advancing its HYLA continuous blood monitoring system, undergoing clinical trials at Sheba Hospital in Israel. HYLA is designed to provide real-time patient insights, and Inspira plans to submit it for FDA approval in 2025.

This deployment underscores Inspira Technologies’ commitment to transforming respiratory and critical care, solidifying its position as a leader in life-support innovation.

You might like this article: KULR and Scripps Research Pioneer Affordable Pyrolytic Carbon Electrodes